Search by Drug Name or NDC
NDC 00069-2522-02 Elrexfio 44 mg/1.1mL Details
Elrexfio 44 mg/1.1mL
Elrexfio is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is ELRANATAMAB.
MedlinePlus Drug Summary
Elranatamab-bcmm is used to treat multiple myeloma (a type of cancer of the bone marrow) that has returned or that did not respond to at least 4 other treatments. Talquetamab-tgvs is in a class of medications called bispecific T-cell engager antibodies. It works by killing cancer cells.
Related Packages: 00069-2522-02Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Elranatamab-bcmm
Product Information
| NDC | 00069-2522 |
|---|---|
| Product ID | 0069-2522_f6fea598-ff58-4a20-b5e8-8a51f37d8beb |
| Associated GPIs | |
| GCN Sequence Number | 085162 |
| GCN Sequence Number Description | elranatamab-bcmm VIAL 44MG/1.1ML SUBCUT |
| HIC3 | V1K |
| HIC3 Description | ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES |
| GCN | 54584 |
| HICL Sequence Number | 049146 |
| HICL Sequence Number Description | ELRANATAMAB-BCMM |
| Brand/Generic | Brand |
| Proprietary Name | Elrexfio |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | elranatamab-bcmm |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 44 |
| Active Ingredient Units | mg/1.1mL |
| Substance Name | ELRANATAMAB |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761345 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-2522-02 (00069252202)
| NDC Package Code | 0069-2522-02 |
|---|---|
| Billing NDC | 00069252202 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0069-2522-02) / 1.1 mL in 1 VIAL, SINGLE-DOSE (0069-2522-01) |
| Marketing Start Date | 2023-08-15 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |